Source: CEIC, National Bureau of Statistics, Morgan Stanley Research China's retail sales growth in November slowed down to +3.0% YoY, vs 4.8% in October, below expectations (vs. consensus at +4.6%), partly due to the front-loading effect of 11.11 promotion into Oct sales. Implied recovery pace vs. 2019 lowered to 115%, vs. 119% in October. Exhibit 1: Summary of Retail Sales Trend Morgan Stanley does and seeks to do business with companies covered in Morgan Stanley Research. As a result, investors should be ...

The property sector remained the weak link in the economy. On the one hand, property sales reversed to pick up, by 3.2% y/y versus a decline of 1.6% in October, the first increase since May 2023. On a sequential basis, declines in both the new- (November: -0.2%, October: -0.5%) and second-home (November: -0.3%, October: -0.5%) prices eased for a second month. The NBS said 58 out of the 70 major cities it monitors reported declines in secondary home prices in the month, which improved slightly from 59 in Oct ...

Asia Pacific Economic Research 16 December 2024 J P M O R G A N Housing price contraction narrowed further, though on the margin... The NBS 70 cities' new home prices inched down 0.2%m/m nsa in November, along with a 0.3% fall in secondary home sales. Both narrowed modestly from the 0.5% fall in October. In %oya terms, new home prices declined 6.1% (vs. -6.2% in October) and secondary home prices declined 8.5% (vs. -8.9% in October). Compared to the previous month, new home prices declined in 49 cities (vs. ...

Citi Research is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Certain products (not inconsistent with the author's published research) are available only on Citi's portals. Companie ...

16 Dec 2024 00:28:37 ET │ 10 pages Activity Improvement Stalls into Year-End CITI'S TAKE Citi Research is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Certain products (not inconsis ...

Source: CEIC, Morgan Stanley Research. E= Hong Kong Govt. estimate Morgan Stanley Research 5 M Foundation Source: HKMA, CEIC, Morgan Stanley Research Source: HKMA, CEIC, Morgan Stanley Research 更多资料加入知识星球：水木调研纪要 关注公众号：水木纪要 summary M Foundation Hong Kong Economics | Asia Pacific December 16, 2024 09:00 PM GMT 2025 Outlook: Duel Challenges Ahead Real GDP growth is set to moderate in 2025-26, as rising USChina trade tensions and increased price competitiveness in Mainland China weigh on investment and consumpt ...

更多资料加入知识星球：水木调研纪要 关注公众号：水木纪要 ab 16 December 2024 Global Research China Economic Perspectives Mixed growth momentum in November Economics China Growth momentum showed a mixed picture in November After better-than-expected growth momentum in October, China had a mixed growth picture in November. Owing to major policy easing in the past several months, property sales growth rebounded to a positive YoY reading with its seasonally adjusted level improving further sequentially, lifting retail sales of related goo ...

This material is neither intended to be distributed to Mainland China investors nor to provide securities investment consultancy services within the territory of Mainland China. This material or any portion hereof may not be reprinted, sold or redistributed without the written consent of J.P. Morgan. backdrop). Our top-picks for China consumer industry: Haier, Midea, YUMC, Anta, Tsingtao (H) and CRB. China Nov offline retail sales were up 6.1% yoy, while online went down by 2.7% yoy, due to the early start ...

更多资料加入知识星球：水木调研纪要 关注公众号：水木纪要 China Ecommerce According to the National Bureau of Statistics (NBS), China online retail sales in 11M24 increased 7.4% YoY to Rmb14,031bn, slower than the 8.8% YoY increase as of October. On a monthly basis, online retail sales in November declined 2% YoY vs. 10% YoY growth in October, reflecting the earlier Singles Day promotion this year. We believe the better way to read the numbers is to look at accumulated online retail sales growth in OctoberNovember, which normalizes the ...

Company and Industry Overview * **Company**: Pfizer Inc. (NYSE:PFE) * **Industry**: Pharmaceuticals, Biotechnology Key Points and Arguments 1. **2024 Financial Guidance Reaffirmed**: Pfizer reaffirmed its full-year 2024 financial guidance, expecting revenues in the range of $61 billion to $64 billion and adjusted diluted earnings per share in the range of $2.75 to $2.95 [16]. 2. **2025 Financial Guidance**: Pfizer provided guidance for 2025, anticipating revenues in the range of $61 billion to $64 billion and adjusted diluted earnings per share in the range of $2.80 to $3.00 per share [19]. 3. **Revenue Growth**: Pfizer expects operational revenue growth of approximately flat to up 5% in 2025, driven by the growth of its oncology and non-COVID vaccine products [19]. 4. **Adjusted Diluted Earnings Per Share Growth**: Pfizer expects adjusted diluted earnings per share to grow operationally by approximately 10% to 18% in 2025, reflecting an operating margin expansion of over 250 basis points versus 2024 [19]. 5. **COVID-19 Products**: Pfizer expects its COVID-19 products, Comirnaty and Paxlovid, to contribute to stable revenue in 2025, with both maintaining their market shares with stable pricing [20]. 6. **Oncology**: Pfizer expects its oncology products, such as Padcev, Lorbrena, and Ibrance, to contribute significantly to growth in the later part of the decade [24]. 7. **Non-COVID Vaccine Products**: Pfizer expects its non-COVID vaccine products, such as Abrysvo and Prevnar, to remain key contributors to its business [22]. 8. **Cost Reduction**: Pfizer achieved its goal of $4 billion in net cost savings by the end of 2024 and expects an additional $500 million in net cost savings in 2025 [11]. 9. **Capital Allocation**: Pfizer remains committed to maintaining and growing its dividend, investing in its business, and de-leveraging its balance sheet [31]. Other Important Content * **Seagen Acquisition**: Pfizer highlighted the successful integration of Seagen and the positive impact of the acquisition on its oncology portfolio [8]. * **Pipeline**: Pfizer discussed its robust pipeline, including several Phase 3 studies and potential new products in various therapeutic areas [9]. * **R&D Leadership**: Pfizer announced the appointment of Dr. Chris Boshoff as its Chief Scientific Officer and President of R&D [9]. * **Capital Return**: Pfizer plans to continue monetizing its stake in Haleon over time, considering its cash flow requirements and future market conditions [31]. * **Drug Pricing**: Pfizer discussed the impact of the IRA Medicare Part D redesign on its revenue and its commitment to transparency and passing savings to patients [53].